Sagimet pivots to acne, raises $175M; MASH trials paused pending non-dilutive funding

Filed May 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

Key Changes

• high

  Company reordered therapeutic priorities to list acne first, reversing prior MASH-first sequence. MASH Phase 3 trials paused until non-dilutive financing secured; R&D spending down 54% year-over-year as MASH work halted.

  MD&A: Strategic Focus & R&D Expenses verify on EDGAR →
• high

  Ascletis received China NDA acceptance for denifanstat in moderate-to-severe acne (December 2025), the first regulatory filing for any denifanstat indication. 52-week Phase 3 safety trial showed drug well-tolerated with efficacy improvements.

  MD&A: China Regulatory Milestones verify on EDGAR →
• high

  Company plans U.S. acne IND filing mid-2026 and registrational Phase 3 trial launch in second half 2026, building on successful China results. Represents new U.S. development program expanding pipeline beyond MASH.

  MD&A: U.S. Acne Program verify on EDGAR →